Female cancer prediction using cervical omics to individualise screening and prevention

Informazioni relative al progetto

FORECEE

ID dell’accordo di sovvenzione: 634570

DOI 10.3030/634570

Progetto chiuso

Data della firma CE 27 Marzo 2015

Data di avvio 1 Settembre 2015

Data di completamento 29 Febbraio 2020

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale € 7 994 746,25

Contributo UE € 7 994 746,25

Coordinato da

UNIVERSITY COLLEGE LONDON
United Kingdom

Risultati finali

Documents, reports (6)

Recommendations for screening policy from legal/regulatory/ethical and women’s perspective
Review on decision-analytic cost-effectiveness

Review on decision-analytic cost-effectiveness studies in women’s cancers (based on current screening/prevention strategies) analysis publication available

Cost-effectiveness in women’s cancer (based on WID test projections) analysis publication available
Leaflet and results from survey and public workshop results
Screening/prevention recommendations based on the WID test available
Scientific publication on the optimal delivery of risk-stratified screening, including consensus guidelines on implementation plan

Websites, patent fillings, videos etc. (3)

Project website
Multimedia presentation available
Formal presentation to the ESGO patient advocacy group (ENGAGe)

Formal presentation to the ESGO patient advocacy group ENGAGe

Pubblicazioni

Peer reviewed articles (7)

Epigenetic Discrimination: Emerging Applications of Epigenetics Pointing to the Limitations of Policies Against Genetic Discrimination

Autori: Charles Dupras, Lingqiao Song, Katie M. Saulnier, Yann Joly
Pubblicato in: Frontiers in Genetics, Numero 9, 2018, ISSN 1664-8021
Editore: Frontiers Media
DOI: 10.3389/fgene.2018.00202

Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review

Autori: Maaike Alblas, Kimberley B. Velt, Nora Pashayan, Martin Widschwendter, Ewout W. Steyerberg, Yvonne Vergouwe
Pubblicato in: Critical Reviews in Oncology/Hematology, Numero 126, 2018, Pagina/e 92-99, ISSN 1040-8428
Editore: Elsevier BV
DOI: 10.1016/j.critrevonc.2018.03.023

Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women’s Cancer: Points to Consider

Autori: Emmanuelle Lévesque, Emily Kirby, Ineke Bolt, Bartha Maria Knoppers, Inez de Beaufort, Nora Pashayan, Martin Widschwendter
Pubblicato in: Public Health Genomics, 2018, Pagina/e 1-8, ISSN 1662-4246
Editore: S. Karger AG
DOI: 10.1159/000492663

Epigenome-based cancer risk prediction: rationale, opportunities and challenges

Autori: Martin Widschwendter, Allison Jones, Iona Evans, Daniel Reisel, Joakim Dillner, Karin Sundström, Ewout W. Steyerberg, Yvonne Vergouwe, Odette Wegwarth, Felix G. Rebitschek, Uwe Siebert, Gaby Sroczynski, Inez D. de Beaufort, Ineke Bolt, David Cibula, Michal Zikan, Line Bjørge, Nicoletta Colombo, Nadia Harbeck, Frank Dudbridge, Anne-Marie Tasse, Bartha M. Knoppers, Yann Joly, Andrew E. Teschendorf
Pubblicato in: Nature Reviews Clinical Oncology, Numero 15/5, 2018, Pagina/e 292-309, ISSN 1759-4774
Editore: Nature Publishing Group
DOI: 10.1038/nrclinonc.2018.30

What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries

Autori: Odette Wegwarth, Martin Widschwendter, David Cibula, Karin Sundström, Rosalba Portuesi, Ines Lein, Felix G Rebitschek
Pubblicato in: BMJ Open, Numero 8/12, 2018, Pagina/e e023789, ISSN 2044-6055
Editore: BMJ Publishing Group
DOI: 10.1136/bmjopen-2018-023789

Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges

Autori: Nora Pashayan, Daniel Reisel, Martin Widschwendter
Pubblicato in: Personalized Medicine, Numero 13/2, 2016, Pagina/e 93-95, ISSN 1741-0541
Editore: Future Medicine Ltd.
DOI: 10.2217/pme.15.53

Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management

Autori: Vit Weinberger, Marketa Bednarikova, David Cibula, Michal Zikan
Pubblicato in: Expert Review of Anticancer Therapy, Numero 16/12, 2016, Pagina/e 1311-1321, ISSN 1473-7140
Editore: Future Drugs Ltd.
DOI: 10.1080/14737140.2016.1247699

Non-peer reviewed articles (1)

Autonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent?

Autori: Maaike Alblas, Maartje Schermer, Yvonne Vergouwe, Ineke Bolt
Pubblicato in: Journal of Personalized Medicine, Numero 9/1, 2019, Pagina/e 14, ISSN 2075-4426
Editore: Jourmal of Personalized Medicine
DOI: 10.3390/jpm9010014